XML 14 R4.htm IDEA: XBRL DOCUMENT v3.22.2.2
Condensed Consolidated Statements of Operations (unaudited) - USD ($)
shares in Millions, $ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Revenues:        
Total revenue $ 156.4 $ 167.3 $ 500.6 $ 529.8
Costs and expenses:        
Research and development expense 20.5 18.8 62.0 61.4
Selling, general, and administrative expense 130.5 180.6 368.2 462.2
Goodwill and long-lived asset impairment charges 0.0 0.0 10.7 1.8
Total costs and expenses 201.4 247.2 589.0 677.2
Operating loss (45.0) (79.9) (88.4) (147.4)
Other income (expense):        
Interest income 1.1 0.2 1.6 0.6
Interest expense (0.8) (1.1) (2.3) (6.1)
Other 0.5 120.6 0.6 139.3
Total other income (expense), net 0.8 119.7 (0.1) 133.8
Income (loss) before income tax (44.2) 39.8 (88.5) (13.6)
Income tax expense (benefit) (9.1) 15.2 (18.8) 6.0
Net income (loss) (35.1) 24.6 (69.7) (19.6)
Net income (loss) attributable to non-controlling interest 0.0 0.0 0.0 0.0
Net income (loss) attributable to Myriad Genetics, Inc. stockholders $ (35.1) $ 24.6 $ (69.7) $ (19.6)
Net income (loss) per share:        
Basic (dollars per share) $ (0.43) $ 0.31 $ (0.87) $ (0.25)
Diluted (dollars per share) $ (0.43) $ 0.30 $ (0.87) $ (0.25)
Weighted average shares outstanding:        
Basic (shares) 80.7 78.8 80.4 77.3
Diluted (shares) 80.7 81.5 80.4 77.3
Molecular diagnostic testing        
Revenues:        
Total revenue $ 156.4 $ 167.3 $ 500.6 $ 505.6
Costs and expenses:        
Cost of revenue 50.4 47.8 148.1 139.9
Pharmaceutical and clinical services        
Revenues:        
Total revenue 0.0 0.0 0.0 24.2
Costs and expenses:        
Cost of revenue $ 0.0 $ 0.0 $ 0.0 $ 11.9